AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03091946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overnight oats with additional dried fruits, nuts and seeds
Description: Oatmeal
Study NCT03091946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cooked cream of rice with additional dried fruits, nuts and seeds
Description: Cooked cream of rice
Study NCT04245826 — intervention group
Intervention type: OTHER
Intervention: Change in LCSBs Intake
Description: Effect of changing LCSBs intake
Study NCT04245826 — intervention group
Intervention type: OTHER
Intervention: Substitute LCSBs for SSBs or Water
Description: Effect of substituting LCSBs for SSBs or Water
Study NCT03535168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.
Study NCT03535168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo for BAY1902607
Study NCT03535168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
Study NCT03508713 — intervention group
Intervention type: DRUG
Intervention: disease modified antirheumatic drugs or biological agents
Description: Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
Study NCT03977051 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
Study NCT03104738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% reduction of basal insulin dose
Description: Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital.
Study NCT00248638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine dipeptide with 15% Clinisol
Description: Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
Study NCT00248638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 15% Clinisol
Description: Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
Study NCT01644500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT01644500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Administered orally
Study NCT01644500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo as Capsules
Description: Placebo for glimepiride is administered orally as one to three capsules daily.
Study NCT01644500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo as SC Injection
Description: Placebo for dulaglutide is administered as one SC injection.
Study NCT00988923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group A: HYPERTHERMIA
Description: All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
Study NCT00988923 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: the intervention tool was switched in off, only bolus was activated
Study NCT02467036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
Study NCT02467036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Treatment
Description: The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
Study NCT01764438 — intervention group
Intervention type: PROCEDURE
Intervention: Primovist-enhanced MRI
Description: Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
Study NCT01599338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
Study NCT03488342 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair for primary inguinal hernia
Description: Repair for primary inguinal hernia
Study NCT02947009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Study
Description: Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
Study NCT02947009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic Study
Description: Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
Study NCT01451853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Low Dose
Description: Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen
Study NCT01451853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Middle Dose
Description: Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Study NCT01451853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 High Dose
Description: Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Study NCT01451853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Study NCT01526538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: 50 mg d-cycloserine
Study NCT01526538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo
Study NCT00919464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure monitoring device
Description: monitoring device inserted to measure thigh compartment pressures
Study NCT00919464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compartmental fracture pressure monitoring
Study NCT00919464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture
Study NCT03143400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius BL 3123
Description: Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
Study NCT04858100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision of the lesion
Description: The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case.
Study NCT04858100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait and see approach
Description: The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression.
Study NCT03937453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI/MRCP
Description: An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
Study NCT02532764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-010
Description: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
Study NCT02532764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT03621748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Anesthesia Protocol
Description: Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
Study NCT03621748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-awake Anesthesia Protocol
Description: Non-awake is general anesthesia as per convention with intubation.
Study NCT00825708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 42 2 sec trains of 20HZ rTMS in 100% MT
Study NCT00825708 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shamTMS
Description: sham TMS session
Study NCT00593281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Add Hylenex to SC injection of Morphine
Study NCT00593281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylenex
Description: Add Hylenex to SC injection of Morphine
Study NCT03852706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LORETA
Description: Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
Study NCT03852706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment-as-usual
Study NCT03852706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment-as-usual
Study NCT02842697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
Study NCT02842697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA
Description: Three-dimensional hepatic vein-portal vein model constructed with CTA images
Study NCT02842697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Portal vein velocity measured by Doppler ultrasound
Study NCT01520051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 3 monthly intravenous infusions of 750 mg
Study NCT01520051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 monthly intravenous infusions with saline
Study NCT05471674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
Study NCT05471674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
Study NCT02788422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Description: Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
Study NCT02788422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
Study NCT03399526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat (ZK 245186, BAY 86-5319)
Description: 0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
Study NCT03399526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednicarbate 0.25% ointment
Description: 0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
Study NCT03399526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05% ointment
Description: 0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
Study NCT03399526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene 0.005% ointment
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
Study NCT03399526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
Study NCT03561883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: oral tablet
Study NCT03561883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet
Study NCT03561883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose PPIs QD
Description: background therapy
Study NCT03561883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-dose PPIs QD
Description: background therapy
Study NCT03103100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: 10 mL of 1% lidocaine
Study NCT03103100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 10 mL of 0.25% bupivacaine
Study NCT03103100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus Lidocaine
Description: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
Study NCT02276677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Single dose, intranasal
Study NCT02276677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, intranasal
Study NCT04835922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Block
Description: : Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)
Study NCT04835922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritract Infiltration
Description: At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
Study NCT02470507 — intervention group
Intervention type: OTHER
Intervention: AKI
Description: development of immune dysregulation and rise in inflammatory markers and activation of immune cells
Study NCT01686841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT00093925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study NCT00093925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine
Study NCT03009448 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Each subject will be interviewed using a semi constructed interview.
Study NCT03978403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches
Study NCT03978403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups
Study NCT03978403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches
Study NCT03978403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
Description: Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose
Study NCT03619252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
Study NCT03619252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibacterial Prophylaxis
Description: Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
Study NCT02060006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5mg daily for 8 weeks
Description: Meloxicam 7.5mg daily for 8 weeks
Study NCT00928954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: increasing to 1200 mg/day
Study NCT00928954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: increasing to 40 mg/day
Study NCT01255475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine/amlodipine
Description: Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
Study NCT01255475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo
Study NCT01346852 — intervention group
Intervention type: DRUG
Intervention: Asthma treatment with an asthma-related medication and at least one asthma controller medication
Description: participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
Study NCT02473211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered once daily
Study NCT02473211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60mg tablet administered once daily
Study NCT02042846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SportWelding Fiji Anchor
Study NCT02524990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based follow-up with SQPT
Description: Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
Study NCT04304963 — intervention group
Intervention type: OTHER
Intervention: NO intervention - observational study
Description: NO intervention - observational study